Trials / Terminated
TerminatedNCT01295060
Long-term Safety and Efficacy Study of Octreotide Implant in Patients With Acromegaly
PHASE IIIB, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF AN 84-MG OCTREOTIDE SUBCUTANEOUS HYDROGEL IMPLANT IN SUBJECTS WITH ACROMEGALY
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Endo Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a long term study to evaluate the safety, tolerability and efficacy of an Octreotide Implant in patients that were previously treated with an Octreotide implant.
Detailed description
Evaluation on the long-term safety and tolerability, including local tolerability of the implant site, of the 84-mg octreotide hydrogel implant in subjects with acromegaly who had been successfully treated with the 84-mg octreotide hydrogel implant in the Phase III study IP107-001.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Octreotide | 84 mg Octreotide Implant |
Timeline
- Start date
- 2011-02-01
- Primary completion
- 2012-04-01
- Completion
- 2012-06-01
- First posted
- 2011-02-14
- Last updated
- 2013-09-20
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01295060. Inclusion in this directory is not an endorsement.